A Cluster-randomised Trial of Interventions to Improve Antimalarial Prescribing With Malaria Tests
NCT01292707 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1152
Last updated 2014-11-19
Summary
Background.
Overdiagnosis of malaria is widespread in health facilities throughout Africa, a situation that is unsustainable given the relatively high cost of artemisinin combination therapy (ACTs) compared to older antimalarials. In addition it often denies patients treatment for their actual illness and generates unreliable data for health planners. For these reasons the National Malaria Control Programme introduced revised guidelines for malaria diagnosis and treatment in 2006 restricting the recommendation for antimalarial treatment in patients over the age of 5 years to those with a positive blood slide or malaria rapid diagnostic tests (RDTs) result. To support this, RDTs will be introduced into primary care health facilities in Tanzania starting in 2009.
The high accuracy of current rapid diagnostic tests (RDTs) provides the potential for a cost-effective solution to the problem of malaria overdiagnosis. However, RDTs with revised guidelines to restrict malaria diagnoses to RDT-positive patients have been unsuccessful unless accompanied by unsustainable levels of supervision and training.
Primary objective.
To conduct a trial of interventions directed at prescribers or prescribers and communities compared to control groups to improve adherence to national guidelines for prescription of antimalarial treatment when supported by RDTs in primary health care facilities in NE Tanzania.
Methods
All 60 participating health facilities will receive RDTs and basic training in their use and a copy of current NMCP/MOH guidelines for each prescribing staff member. A health worker intervention arm will, in addition, receive workplace-based interactive training and messages from senior staff A health worker-community arm will receive the same training as the health worker arm and in addition leaflets will be provided to RDT-tested patients providing information on the test and the treatment given. All training materials will be approved by NMCP in Tanzania as being consistent with current national guidelines but with the addition that prescribers will be asked to follow RDT results in prescribing for patients of any age This policy is in line with the most recent revision to WHO guidelines and is supported by NMCP in Tanzania.
Study outcomes will be recorded through a 40% (2 days per week) exit survey of patients. Anthropological and economics studies will assess the costs and acceptability of interventions.
Conditions
Interventions
- BEHAVIORAL
-
Control
Standard national training
- BEHAVIORAL
-
HW
Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
- BEHAVIORAL
-
HWC
The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
Sponsors & Collaborators
-
Kilimanjaro Christian Medical Centre, Tanzania
collaborator OTHER -
Ministry of Health, Tanzania
collaborator OTHER_GOV -
London School of Hygiene and Tropical Medicine
lead OTHER
Principal Investigators
-
Hugh Reyburn, MD · London School of Hygiene and Tropical Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-02-28
- Primary Completion
- 2012-02-29
- Completion
- 2012-04-30
Countries
- Tanzania
Study Locations
More Related Trials
-
Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period
NCT01038063 ·Status: UNKNOWN ·Phase: PHASE4
-
Providers' Compliance to Malaria Treatment
NCT02298140 ·Status: UNKNOWN ·Phase: NA
-
Use of Rapid Diagnostic Tests for Malaria Case Management in Kenya
NCT00336388 ·Status: COMPLETED ·Phase: NA
-
Adherence to Antimalarial Drugs in Sierra Leone
NCT01967472 ·Status: COMPLETED ·Phase: NA
-
Research on the Economics of Artemisinin Combination Therapy (ACTs) for the Treatment of Malaria
NCT01350752 ·Status: COMPLETED ·Phase: NA
-
Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial
NCT00832754 ·Status: COMPLETED ·Phase: PHASE4
-
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
NCT02974348 ·Status: COMPLETED ·Phase: PHASE3
-
"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
NCT03241901 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo
NCT02940756 ·Status: COMPLETED ·Phase: PHASE4
-
Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania
NCT05874869 ·Status: COMPLETED ·Phase: NA
-
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial AIM 1
NCT03810014 ·Status: COMPLETED ·Phase: NA
-
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
NCT03923725 ·Status: COMPLETED ·Phase: PHASE3
-
Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania
NCT00885287 ·Status: COMPLETED ·Phase: PHASE4
-
PDMC Implementation Trial in Kenya
NCT06624631 ·Status: RECRUITING ·Phase: PHASE4
-
Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
NCT00297882 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria
NCT00140361 ·Status: COMPLETED ·Phase: PHASE4
-
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria
NCT04428385 ·Status: COMPLETED ·Phase: NA
-
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria
NCT00203736 ·Status: COMPLETED ·Phase: NA
-
Compliance to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana
NCT00873938 ·Status: COMPLETED
-
Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs
NCT00720811 ·Status: COMPLETED ·Phase: NA
-
Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers
NCT00301015 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children
NCT04167566 ·Status: COMPLETED ·Phase: NA
-
Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs
NCT01065116 ·Status: COMPLETED ·Phase: PHASE3
-
Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination
NCT03576313 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi
NCT00164710 ·Status: COMPLETED ·Phase: PHASE4